Illumina 's ( ILMN ) CEO Jay Flatley on Q3 2014 Results - Earnings Call Transcript
Illumina ( ILMN ) Q3 2014 Results - Earnings Call Webcast
AAPL , BRO , BXS , CDNS , CE , CMG , CYS , ELS , EWBC , GLF , HLX , HSTM , HXL , ILMN , KALU , PCH , PKG , RCII , RMBS , STLD , TXN , UCTT , WERN , ZION Post your comment!
Ilumina (NASDAQ: ILMN ) will report Q3 results on October 20 after the close. The conference call will begin at 2:00 pm PT. Consensus view is EPS of $0.56 on revenues of $451M. Post your comment!
* Subsidiary Helixio buys an Illumina sequencer Further company coverage: (Gdynia Newsroom: +48 58 698 39 20)
eventually, we believe it could be a long-term positive for ICON by driving greater outsourcing. Waterhouse : I think Illumina ILMN is an interesting company. We think llumina is currently monopolizing the genome sequencing space. This industry
Illumina posted impressive second-quarter results that ..... estimate. We think plenty of tailwinds remain for Illumina over the coming years as the genome sequencing market continues to expand, Illumina takes market share, and upcoming regulatory
the market in mid- to late 2015, considerably behind our own estimate and management's previous expectations. We think Illumina 's recent advances in the sequencing market combined with Qiagen's further delays will make it harder for the company to
(Reuters) - Life-science tool maker Illumina Inc reported a better-than-expected jump in quarterly revenue, helped by strong sales of its gene-sequencing products.
Illumina ’s fourth-quarter results came in mostly ..... investor day. As we previously stated, Illumina ’s current growth has exceeded our expectations ..... projections. We also plan to further reevaluate Illumina ’s longer-term opportunity in the genome